Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Richard

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|November 18, 2009
Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitorsArie Zask, Joshua Kaplan, Jeroen C Verheijen, et al.
Bioorganic & Medicinal Chemistry|September 3, 2013
Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarkerDavid J Richard, Ryan Lena, Thomas Bannister, et al.
Experimental Hematology|November 16, 2024
FT-4202, a selective pyruvate kinase R activator for sickle cell diseaseAnna Ericsson, David J Richard, Erik Wilker, et al.
Journal of Medicinal Chemistry|November 10, 2009
Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituentJeroen C Verheijen, David J Richard, Kevin Curran, et al.
Journal of Medicinal Chemistry|August 4, 2009
ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidinesArie Zask, Jeroen C Verheijen, Kevin Curran, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|November 18, 2009
Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitorsArie Zask, Joshua Kaplan, Jeroen C Verheijen, et al.
Bioorganic & Medicinal Chemistry|September 3, 2013
Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarkerDavid J Richard, Ryan Lena, Thomas Bannister, et al.
Experimental Hematology|November 16, 2024
FT-4202, a selective pyruvate kinase R activator for sickle cell diseaseAnna Ericsson, David J Richard, Erik Wilker, et al.
Journal of Medicinal Chemistry|November 10, 2009
Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituentJeroen C Verheijen, David J Richard, Kevin Curran, et al.
Journal of Medicinal Chemistry|August 4, 2009
ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidinesArie Zask, Jeroen C Verheijen, Kevin Curran, et al.
Pageof 2